How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles

In this FAQ Video Module, Christy Vath, PA-C, a seasoned rheumatology expert from Seattle Rheumatology Associates, explores how the selectivity of TYK2 and JAK enzyme inhibition impacts safety profiles. She provides a clear comparison between traditional pan-JAK inhibitors and selective TYK2 inhibitors like deucravacitinib, highlighting their differing mechanisms of action and clinical implications.

Christy breaks down how TYK2’s selective inhibition of the pseudokinase domain—versus the broader catalytic inhibition seen with JAK1, JAK2, and JAK3—can reduce risks associated with immunosuppression, such as major adverse cardiovascular events (MACE), malignancy, and thrombosis. She reviews safety findings from pivotal clinical trials in plaque psoriasis and psoriatic arthritis, where deucravacitinib demonstrated a favorable safety profile and limited systemic immunosuppressive effects.

Watch now to understand why TYK2 selectivity matters—and how it may shape the future of treatment in immune-mediated diseases like psoriasis and PsA.